

2026 Annual General Shareholders' Meeting

Faes Farma holds its Annual General Shareholders' Meeting following a key year in the execution of its Strategic Plan

- **Shareholders approved all items on the agenda, including the 2025 annual accounts, as well as the appointment of Jacobo Llanza and Ángel Agudo as members of the Board of Directors.**
- **The Meeting also approved the payment of a complementary dividend of €0.087 per share. This brings the total shareholder remuneration to €0.128 per share, equivalent to a 50% pay-out.**
- **The Group expects to accelerate its growth in 2026, with revenue increasing by between 17% and 19% and EBITDA improving by between 28% and 31%.**

Bilbao, 25 June 2026. – Faes Farma held its Annual General Shareholders' Meeting today after closing a financial year marked by the execution of the first year of its 2025–2030 Strategic Plan, through which it aims to be recognised as the leading Spanish pharmaceutical company on a global scale.

During the meeting held in Bilbao, shareholders approved all the items on the agenda, including the 2025 annual accounts, the re-election of three independent directors and the Chairman, as well as the appointment of two new proprietary directors.

Faes Farma's CEO, Eduardo Recoder, reviewed the main achievements and financial results for the 2025 financial year during his speech. Last year, Faes Farma increased its revenue by 23% to €627 million, driven both by the organic performance of the business and by the incorporation of SIFI and Edol. The Group closed the year with net debt of €267 million and leverage of around 2x EBITDA, maintaining a solid financial position and comfortable liquidity.

"2025 has been a year of profound transformation and, above all, of real execution. A year in which we have not only defined where we want to go, but in which we have also taken firm

steps to get there. We have made important decisions, undertaken historic acquisitions and, throughout, remained focused on what matters most: building a stronger competitive foundation, better prepared to face the years ahead with confidence," said Eduardo Recoder.

Faes Farma has made progress across the main pillars of its roadmap, combining international growth, scientific strengthening and the enhancement of its commercial, operational and industrial capabilities. Among the key milestones of the period are the acquisitions of SIFI and Laboratorio Edol, which have expanded its international presence and strengthened its position in ophthalmology; the boost to R&D, with a particular focus on high value-added therapeutic areas; the evolution towards a more scalable, data-driven commercial model; and the progress of the new Derio manufacturing facility, which will increase production capacity and improve the company's operational efficiency.

Shareholder support

In recognition of the Company's strong performance during the year, Faes Farma approved the distribution of a total dividend charged to 2025 earnings of €0.128 per share, representing a 50% pay-out of net profit. This remuneration consists of a cash dividend of €0.041 per share paid in January 2026 and a complementary cash dividend of €0.087 per share, which will be paid on 6 July.

The Company's stock market performance was also noteworthy, with its share price appreciating by 48% in 2025 and reaching a market capitalisation of €1.632 billion at year-end. This performance reflects the market's confidence in the Group's strategy, execution and ability to create value.

2026 outlook

Looking ahead to 2026, Faes Farma maintains its guidance, which includes revenue growth of between 17% and 19%, EBITDA improvement of between 28% and 31%—including the remaining extraordinary costs associated with Derio—and net debt below two times EBITDA.

The main growth drivers for the year will be expansion in key markets, the full integration of SIFI and Edol, the capture of commercial synergies, SIFI's growth supported by the launches of Akantior, and the continuous improvement of operational efficiency.

"We are executing well on what we have already built and continue to move forward, with ambition and determination, towards a more global, more efficient Faes Farma with an even greater capacity to generate sustainable long-term value," said Eduardo Recoder.

About Faes Farma

We are a company with more than 90 years of experience and a presence in over 130 countries through marketed or licensed products. We combine passion, science and innovation to transform people's health. We research, manufacture and market prescription medicines, healthcare products and animal nutrition products, and we aspire to become a leading pharmaceutical Group recognised for excellence and innovation. At Faes Farma, we are guided by our values to provide the highest-quality healthcare and wellbeing solutions, always putting patients first; to develop innovative products that respond to society's needs; and to ensure an ethical, transparent and committed business activity through responsible management and operational excellence.

Media contacts

María Marín

Head of Investor Relations and External Communication

mmarin@faes.es

Faes Farma

Paula Lacruz

placruz@harmon.es

626 12 93 00

Harmon Corporate Affairs